tpm 02 insulin

Text from: http://www.cnbc.com/id/36938081

Below is a long and distinguished list of all companies who currently have an R&D Pipline for Diabetes Treatments.

True, on first impressions it appears we are a small fish in a big pond.

Pohster may be able to shed some light on our competition and better explain how far up the food chain we are in the insulin pond?

For instance if we were ahead of the game compared to others who would be likely partners from the R&D List below?

Reportlinker Adds World Diabetes Market Analysis 2010-2025 By: PR Newswire | 04 May 2010 | 10:19 AM ET Text Size NEW YORK, May 4, 2010 /PRNewswire via COMTEX/ --

Reportlinker.com announces that a new market research report is available in its catalogue: World Diabetes Market Analysis 2010-2025 http://www.reportlinker.com/p0191595/World-Diabetes-Market-Analysis-2010-2025.html

How will the diabetes market develop, with rising disease prevalence in many countries? In 2009, the diabetes treatment market generated worldwide sales of over $25 billion, with strong growth from the previous year. The incidence and prevalence of diabetes mellitus are on the rise worldwide, in line with lifestyle changes and ageing populations. In particular, the increasing prevalence of diabetes is closely linked with that of obesity, creating significant market opportunities in developed nations and some developing countries. The World Health Organization estimates the number of diabetics to exceed 350 million by 2030.

The R&D Pipeline for Diabetes Treatments

8.1 The Anti-Diabetic Drugs Pharmaceutical Pipeline

8.2 The Human Insulins and Analogues Pipeline

8.2.1 Technosphere Insulin (Mankind)
8.2.2 VIAject/VIAdel (Biodel)
8.2.3 CKD 401(Chong Kun Dang)
8.2.4 BHT 3021/RG 7426 (Bayhill Therapeutics/Genentech)
8.2.5 Nasulin/CPE-215 (CPEX Pharmaceuticals)
8.2.6 Capsulin (Diabetology)
8.2.7 ORMD 0801 (Oramed)
8.2.8 TPM 02/Insulin (Phosphagenics)
8.2.9 IN 105 (Biocon)
8.2.10 NN 1250 (Novo Nordisk)
8.2.11 NN 5401 (Novo Nordisk)
8.2.12 SBS 1000 (SemBioSys)

8.3 The Glitazone Anti-Diabetics Pipeline

8.3.1 ACTOplus met XR (Takeda)
8.3.2 Balaglitazone/DRF 2593 (Dr Reddy's/Nordic Bioscience)
8.3.3 MK 0431C (Merck & Co)
8.3.4 MSDC 0160 (Metabolic Solutions Development)
8.3.5 Lobeglitazone/CKD 501 (Chong Kun Dang)
8.4 DPP-IV Inhibitor Anti-Diabetics Pipeline
8.4.1 SYR 322 (Takeda)
8.4.2 Alogliptin (Takeda)
8.4.3 Linagliptin/BI 1356 BS (Boehringer Ingelheim)
8.4.4 Dutogliptin/PHX 1149 (Phenomix)
8.4.5 LC 15 0444 (LG Life Sciences)
8.4.6 Saxagliptin and Metformin Combination
8.4.7 MK 0431C (Merck & Co)
8.4.8 SK 0403 (Sanwa Kagaku/ Kowa/ Choongwae)
8.4.9 Teneligliptin/MP 513 (Mitsubishi Tanabe Pharma)
8.4.10 ALS 20426/AMG 222 (Amgen)
8.4.11 Carmegliptin/R 1579 (Roche)
8.4.12 KRP 104 (Kyorin)
8.4.13 Melogliptin/GRC 8200 (Glenmark)
8.4.14 SYR 472 (Takeda)
8.4.15 TA 6666 (Mitsubishi Tanabe Pharma)

8.5 Sulphonylurea and Biguanide Anti-Diabetics Pipeline

8.5.1 NCT00660907/Dapagliflozin + Metformin Combination (AstraZeneca)
8.5.2 Metformin XL (Flamel Technologies)
8.5.3 Metcontrol (Generex Biotechnology)
8.6 Alpha-glucosidase Inhibitor Anti-Diabetics Pipeline
8.6.1 KMV 0207 (Kissei/Takeda)
8.6.2 PharmaLinks Compounds (University of Strathclyde)

8.7 Miscellaneous Class of Anti-Diabetic Drugs in the R&D Pipeline

8.7.1 Byetta LAR/AC 2993 LAR (Amylin/Alkermes/Eli Lilly)
8.7.2 Albiglutide/GSK 716155 (GlaxoSmithKline)
8.7.3 Lixisenatide/ZP 10/AVE 0010 (sanofi-aventis)
8.7.4 LY 2189265 (Eli Lilly)
8.7.5 Taspoglutide/ BIM 51077 (Roche)
8.7.6 ITCA 650 (Intarcia)
8.7.7 Gosogliptin/PF 734200 (Pfizer)
8 7.8 Semaglutide/NN 9535 (Novo Nordisk)
8.7.9 Bromocriptine/Cycloset (VeroScience/ S2 Therapeutics)
8.7.10 SF 1019/R-1818 (Argyll Biotechnologies)
8.7.11 Arhalofenate/MBX 102 (Metabolex and Ortho-McNeil)
8.7.12 Canagliflozin/TA 7284 (Mitsubishi Tanabe Pharma/ Johnson & Johnson)
8.7.13 Dapagliflozin (Bristol-Myers Squibb)
8.7.14 DiaPep277 (Andromeda/ DeveloGen)
8.7.15 Mirabegron/YM 178 (Astellas)
8.7.16 Otelixizumab/TRX 4/ChAglyCD3 (GlaxoSmithKline/Tolerx/BTG)
8.7.17 Teplizumab/MGA 031 (MacroGenics/Eli Lilly)
8.7.18 DIAMYD/GAD65 (Diamyd Medical)